LTP

5.88%

90.0¢ ltr pharma limited

Ann: LTR Pharma to List on the ASX, page-136

First 136 Last

Share
Profile

Follow
Rorbag

1,296 Posts.

245

19/02/24

14:12

Post #: 72484536
Share

Originally posted by JackBNimble: ↑

agree it has been a good start but I did expect more. Reason being the asymmetric risk/reward profile. If it doesnt work for whatever reason it gets nailed. If it gets approved they're selling it in Aus in June/July, the US late 2024 and I presume the other major markets thereafter.

I calculate 5% market share would be USD225m EBITDA. If we use a multiple of 10 that is a mkt cap of USD 2.2B or AUD 3.4b for a company currently valued at AUD 42m (off 30c). Lets halve that for arguments sake and its still so silly I cant bring myself to write how many times it could multiply. What if it got more - 10, 20% etc with a better product?

Thats all fine but what are the odds of approval? Impossible to calculate accurately but the trial is to assess safety and if the drug can effectively enter the bloodstream via the mucous membrane. They proved the later in 2020 so its reasonable to say its probable in this setting.

So I simply look at it like this - if its not approved I take a hit. If its approved I believe it will multiply many times and I believe I have a better than 50:50 chance of approval. I'd take odds half as good every single time and if correct I think it should be trading higher.

Note - I have been long since pre IPO (2.5 years) and added after IPO. I am wrong more than I would like. This sort of potential downside risk is not for most ie dont risk what you cant afford to lose. The pain is real when wrong - believe me on nothing more than that. Verify everything else Ive written above and plz tell me if Im wrong with evidence and try to be civil. Its ok to have a different view, you can short it through a CFD broker if you do - (I wouldnt because of the above).

Expand

I like your excitement . Needs patent protection. FDA approval process is arduous. 150day approval period once FDA approved clinical trials are completed so unlikely to see USA market penetration until mid to late 2025 IF THEY GET FDA APPROVAL. Very interesting watch this one.

Reminder of timeline attached

LTP Price at posting: 30.0¢ Sentiment: None Disclosure: Not Held
5 Upvote

0 Great analysis

Reply

Top Stories

LLL

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

KGL

KGL sniffs 19% Cu from drilling at Rockface play in NT

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

RHI

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

TVN

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Climate change to drive market trends to the moon

STN

Saturn’s stars have aligned for the gold explorer’s Apollo Project

ITM

Fast-track assaying yields 182 g/t gold for iTech at new NT play

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

There are more pages in this discussion • 10 more messages in this thread...

First 136 Last

Add LTP (ASX) to my watchlist

(20min delay)
Last 90.0¢		Change 0.050(5.88%)		Mkt cap ! $63.36M

Open	High	Low	Value	Volume
85.0¢	91.0¢	85.0¢	$342.6K	389.4K

Buyers (Bids)

No.	Vol.	Price($)
3	44999	90.0¢

Sellers (Offers)

Price($)	Vol.	No.
92.0¢	10000	1

View Market Depth

No.	Vol.	Price($)
3	44999	0.900
1	5000	0.890
1	3000	0.855
1	591	0.845
2	938	0.840

Price($)	Vol.	No.
0.920	10000	1
0.930	2850	1
0.940	2500	1
0.950	11100	2
0.960	11155	2

Last trade - 16.10pm 05/07/2024 (20 minute delay)

LTP (ASX) Chart

Ann: LTR Pharma to List on the ASX, page-136

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

KGL sniffs 19% Cu from drilling at Rockface play in NT

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Climate change to drive market trends to the moon

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Fast-track assaying yields 182 g/t gold for iTech at new NT play

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: LTR Pharma to List on the ASX, page-136

Top Stories

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

KGL sniffs 19% Cu from drilling at Rockface play in NT

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Climate change to drive market trends to the moon

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Fast-track assaying yields 182 g/t gold for iTech at new NT play

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News